If you have CLL and have been treated with either ibrutinib (Imbruvica) or venetoclax (ABT-199) we need your help.
Lymphoma Canada is preparing submissions for the panCanadian Oncology Drug Review (pCODR) for:
1.Ibrutinib (Imbruvica) for patients with previously untreated CLL for whom fludarabine-based treatment is considered inappropriate
2.Venetoclax (ABT-199) for patients with relapsed/refractory CLL.
You can help by completing our survey, which will provide us with the patient input required for the submissions. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THESE TREATMENTS IN CANADA.
You do not need to live in Canada to complete this survey.
The survey will be open until midnight Pacific Time on Wednesday, April 20th and should only take 10 minutes of your time.
Please share this link ( surveymonkey.com/r/SRWKYMX) and help us spread the word.
Thank you for your support.